Bank Of Nova Scotia Ovid Therapeutics Inc. Transaction History

Bank Of Nova Scotia

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$3.23 - $3.97 $429 - $528	133 Added 0.3%	44,152 $169,000
Q2 2023 Aug 03, 2023	BUY	$2.53 - $3.89 $1,677 - $2,579	663 Added 1.53%	44,019 $144,000
Q1 2023 May 11, 2023	SELL	$1.88 - $2.85 $3,995 - $6,056	-2,125 Reduced 4.67%	43,356 $111,000
Q4 2022 Feb 09, 2023	BUY	$1.43 - $1.89 $227 - $300	159 Added 0.35%	45,481 $84,000
Q3 2022 Nov 10, 2022	BUY	$1.84 - $2.26 $423 - $519	230 Added 0.51%	45,322 $83,000
Q2 2022 Aug 05, 2022	SELL	$1.69 - $3.31 $3,816 - $7,473	-2,258 Reduced 4.77%	45,092 $97,000
Q1 2022 May 09, 2022	BUY	$2.65 - $3.49 $13,578 - $17,882	5,124 Added 12.13%	47,350 $149,000
Q4 2021 Feb 11, 2022	BUY	$3.13 - $3.73 $132,167 - $157,502	42,226 New	42,226 $136,000

39M

37.4K

500

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $73.2M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

Stay updated on Bank Of Nova Scotia with notifications on news.